In January, the FDA approved cabotegravir/rilpivirine (Cabenuva®), the first long-acting medication used for treating HIV infection. Several long-acting modalities are currently under investigation for both HIV treatment and prophylaxis, including oral, injectable, implant, antibody therapy, and vaginal ring.
Long-acting formulations are being developed to overcome barriers—primarily, adherence—presented by daily oral therapy. Encouraging results regarding adherence comes from the phase IIb LATTE-2 study (NCT02120352) evaluating long-acting cabotegravir-rilpivirine for HIV treatment where 99% of participants preferred to continue with injectable therapy compared with 78% on oral treatment.
The purpose of this article is to provide an overview of the various ART therapies being studied and available for prevention and treatment of HIV.
Read the full story at Contagion Live.
Source : Contagion Live
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.